News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vivendy Therapeutics AG's Treatment for Morbus Morquio (MPS IVA) Granted Orphan Drug Designation by FDA



9/17/2008 8:59:33 AM

BASEL, Switzerland--(BUSINESS WIRE)--Vivendy Therapeutics Ltd. today announced that its enzyme replacement therapy (ERT) for Mucopolysaccharidosis IVA, (MPS IVA-Morbus Morquio) has been granted Orphan Drug designation by the United States Food and Drug Administration (FDA). This designation, following potential marketing approval in the future will give Vivendy seven years of market exclusivity and could facilitate the recovery of certain regulatory filing fees.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES